ADP-ribosyl transferase fusion variant proteins
The present invention relates to novel chimeric C3-like Rho antagonists and their use for promoting repair and neuron survival in injured mammalian central and peripheral nervous system and for treating or preventing cancer.
1. An isolated polypeptide selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:18, and SEQ ID NO:20.
2. The isolated polypeptide of claim 1 , wherein the polypeptide selected from the group consisting of SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:18, and SEQ ID NO:20 is truncated by 20 amino acids at its N-terminus.
3. The isolated polypeptide of claim 1 , wherein the polypeptide selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:18, and SEQ ID NO:20 is truncated by 10 amino acids at its C-terminus.
4. The isolated polypeptide of claim 1 , wherein the polypeptide selected from the group consisting of SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:18, and SEQ ID NO:20 is truncated by 20 amino acids at its N-terminus and 10 amino acids at its C-terminus.
5. The isolated polypeptide of claim 1 , wherein said polypeptide is PEGylated.
6. A pharmaceutical composition comprising (a) an isolated polypeptide selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:18, and SEQ ID NO:20 and (b) a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6 , wherein the polypeptide selected from the group consisting of SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:18, and SEQ ID NO:20 is truncated by 20 amino acids at its N-terminus.
8. The pharmaceutical composition of claim 6 , wherein the polypeptide selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:18, and SEQ ID NO:20 is truncated by 10 amino acids at its C-terminus.
9. The pharmaceutical composition of claim 6 , wherein the polypeptide selected from the group consisting of SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:18, and SEQ ID NO:20 is truncated by 20 amino acids at its N-terminus and 10 amino acids at its C-terminus.
10. The pharmaceutical composition of claim 6 , wherein the polypeptide is PEGylated.
11. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is sterile, sterilizable or sterilized.
12. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is in a vial in a unit dosage amount or in an integral multiple of a unit dosage amount.
13. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is dried or comprises a dehydrated matrix.
14. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition comprises a fusion protein and wherein the fusion protein comprises the isolated polypeptide selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:14, SEQ ID NO:18, and SEQ ID NO:20 in a lyophilized matrix.
15. An isolated polypeptide consisting of SEQ ID NO: 10.
16. The isolated polypeptide of claim 15 , wherein the polypeptide consisting of SEQ ID NO:10 is truncated by 20 amino acids at its N-terminus.
17. The isolated polypeptide of claim 15 , wherein the polypeptide consisting of SEQ ID NO:10 is truncated by 10 amino acids at its C-terminus.
18. The isolated polypeptide of claim 15 , wherein the polypeptide consisting of SEQ ID NO:10 is truncated by 20 amino acids at its N-terminus and 10 amino acids at its C-terminus.
19. The isolated polypeptide of claim 15 , wherein said polypeptide is PEGylated.
20. A pharmaceutical composition comprising (a) an isolated polypeptide consisting of SEQ ID NO:10 and (b) a pharmaceutically acceptable carrier.
21. The pharmaceutical composition of claim 20 , wherein the polypeptide consisting of SEQ ID NO:10 is truncated by 20 amino acids at its N-terminus.
22. The pharmaceutical composition of claim 20 , wherein the polypeptide consisting of SEQ ID NO:10 is truncated by 10 amino acids at its C-terminus.
23. The pharmaceutical composition of claim 20 , wherein the polypeptide consisting of SEQ ID NO:10 is truncated by 20 amino acids at its N-terminus and 10 amino acids at its C-terminus.
24. The pharmaceutical composition of claim 20 , wherein said polypeptide is PEGylated.
25. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is sterile, sterilizable, or sterilized.
26. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is in a vial in a unit dosage amount or in an integral multiple of a unit dosage amount.
27. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is dried or comprises a dehydrated matrix.
28. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition comprises a fusion protein and wherein the fusion protein comprises the isolated polypeptide consisting of SEQ ID NO:10 in a lyophilized matrix.
29. An isolated nucleic acid selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, and SEQ ID NO: 37.